North America Molecular Diagnostics Market Report Up to 2031: Visiongain Research Inc


Visiongain has published a new report on “North America Molecular Diagnostics Market, 2021-2031”. Forecasts By Technology {Polymerase Chain Reaction (Multiplex PCR, Other PCR), Isothermal Nucleic Acid Amplification Technology,In Situ Hybridization, Mass Spectrometry,Chips and Microarrays, Transcription Mediated Amplification, Sequencing, Others}, Application {Oncology (Prostate Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Liver Cancer, Kidney Cancer, Lung Cancer, Blood Cancer, Other Cancer), Pharmacogenomics, Infectious Diseases (Clostridium Difficile,Methicillin-resistant Staphylococcus Aureus, Carbapenem-resistant Bacteria, Vancomycin-resistant Enterococci, Flu, Candida, Respiratory Syncytial Virus, Meningitis,Tuberculosis and Drug-Resistant TBA, Chlamydia, Gastrointestinal Panel Testing, HIV, Gonorrhoea, Hepatitis B, Hepatitis C, Other Infectious Diseases), Genetic Testing (Predictive and Pre-symptomatic Testing, New-born Screening, Other Genetic Testing), Neurological Disease, Cardiovascular Diseases, Microbiology, Others}, Product (Instruments, Reagents), Test Location (Point-of-Care, Over the Counter, Central Laboratories), by Country (U.S., Canada), PLUS COVID-19 Recovery Scenarios.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/north-american-mdx-market-2021/#download_sampe_div

COVID-19 Outbreak to Offer Lucrative Growth Opportunities?

  • Essential Role of Diagnostics in Control of Communicable Diseases
  • Growing Public and Clinical Needs to Drive Molecular Diagnostics Market Growth
  • Deployment of SARS-CoV-2 Diagnostics Anticipated to Curb the Epidemic Across Geographies

Molecular Diagnostics to Improve Healthcare Outcomes

To improve health outcomes, molecular diagnostic testing for genetic or pathogenic diseases is necessary to provide easy, fast and reliable testing, particularly in the developed world. For clinical diagnosis of different pathologies, rapid identification of nucleic acids is important. To avoid undertreatment, it is important to recognise persons who need medication for particular pathologies. The quantity of overtreatment that occurs in resistant micro-organisms can also be minimised. This is anticipated to fuel North American molecular diagnostics market over the forecast period from 2021 to 2031.

Get Detailed TOC @ https://www.visiongain.com/report/north-american-mdx-market-2021/#download_sampe_div

Get Insight into the Competitive Landscape, read this report today.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the North American molecular diagnostics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the molecular diagnostics market.For example, on 1stSeptember 2020, Biocartis Group NV announced the extension of its partnership with LifeArc, an international medical research charity headquartered in the United Kingdom, with a new arrangement aimed at developing highly advanced prototype assays for infectious and immune-related diseases on the fully automated IdyllaTM molecular diagnostics platform of Biocartis.

Companies Profiled

  • Roche Diagnostics
  • Abbott
  • Becton, Dickinson, and Company
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Dako (Agilent Technologies)
  • Danaher
  • FOUNDATION MEDICINE, INC.
  • Genomic Health (Exact Sciences Corporation)
  • Hologic, Inc.
  • Illumina, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Grifols, S.A.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Sysmex Corporation

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the molecular diagnostic market and leading companies. You will get the most recent data, opportunities, trends, and predictions.

Find more Visiongain research reports on Pharma Diagnostics Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.